nodes	percent_of_prediction	percent_of_DWPC	metapath
Bosutinib—Vandetanib—FMO3—metabolic syndrome X	0.0114	0.85	CrCbGaD
Bosutinib—BMPR2—artery—metabolic syndrome X	0.00555	0.0152	CbGeAlD
Bosutinib—BMPR2—blood vessel—metabolic syndrome X	0.00433	0.0118	CbGeAlD
Bosutinib—Chest discomfort—Metformin—metabolic syndrome X	0.00408	0.0551	CcSEcCtD
Bosutinib—PTK2—endothelium—metabolic syndrome X	0.00373	0.0102	CbGeAlD
Bosutinib—PTK2—blood vessel—metabolic syndrome X	0.00344	0.0094	CbGeAlD
Bosutinib—SRC—artery—metabolic syndrome X	0.00342	0.00933	CbGeAlD
Bosutinib—EPHB4—endothelium—metabolic syndrome X	0.0034	0.00927	CbGeAlD
Bosutinib—EPHB4—blood vessel—metabolic syndrome X	0.00313	0.00855	CbGeAlD
Bosutinib—EPHA2—blood vessel—metabolic syndrome X	0.00307	0.00839	CbGeAlD
Bosutinib—BMX—cardiovascular system—metabolic syndrome X	0.00297	0.00811	CbGeAlD
Bosutinib—PHKG1—cardiovascular system—metabolic syndrome X	0.0029	0.00793	CbGeAlD
Bosutinib—SRC—endothelium—metabolic syndrome X	0.00289	0.00789	CbGeAlD
Bosutinib—TLK1—adipose tissue—metabolic syndrome X	0.00283	0.00773	CbGeAlD
Bosutinib—PRKCQ—adipose tissue—metabolic syndrome X	0.00279	0.00762	CbGeAlD
Bosutinib—SRMS—kidney—metabolic syndrome X	0.00278	0.00759	CbGeAlD
Bosutinib—Renal impairment—Metformin—metabolic syndrome X	0.00276	0.0372	CcSEcCtD
Bosutinib—SIK2—adipose tissue—metabolic syndrome X	0.00275	0.00752	CbGeAlD
Bosutinib—CDK2—cardiovascular system—metabolic syndrome X	0.0027	0.00738	CbGeAlD
Bosutinib—SYK—kidney—metabolic syndrome X	0.00267	0.00729	CbGeAlD
Bosutinib—SRC—blood vessel—metabolic syndrome X	0.00266	0.00727	CbGeAlD
Bosutinib—CDK2—kidney—metabolic syndrome X	0.00265	0.00722	CbGeAlD
Bosutinib—STK26—kidney—metabolic syndrome X	0.00262	0.00716	CbGeAlD
Bosutinib—BMX—adipose tissue—metabolic syndrome X	0.00262	0.00715	CbGeAlD
Bosutinib—CLK3—adipose tissue—metabolic syndrome X	0.00262	0.00715	CbGeAlD
Bosutinib—DSTYK—adipose tissue—metabolic syndrome X	0.00262	0.00715	CbGeAlD
Bosutinib—DMPK—cardiovascular system—metabolic syndrome X	0.00257	0.00701	CbGeAlD
Bosutinib—WEE1—cardiovascular system—metabolic syndrome X	0.00257	0.00701	CbGeAlD
Bosutinib—CASK—adipose tissue—metabolic syndrome X	0.00256	0.00699	CbGeAlD
Bosutinib—EIF2AK1—adipose tissue—metabolic syndrome X	0.00253	0.00691	CbGeAlD
Bosutinib—FES—adipose tissue—metabolic syndrome X	0.00245	0.0067	CbGeAlD
Bosutinib—VRK2—adipose tissue—metabolic syndrome X	0.00245	0.0067	CbGeAlD
Bosutinib—Dehydration—Metformin—metabolic syndrome X	0.00244	0.0329	CcSEcCtD
Bosutinib—SYK—adipose tissue—metabolic syndrome X	0.00241	0.00657	CbGeAlD
Bosutinib—Abdominal pain upper—Metformin—metabolic syndrome X	0.00239	0.0323	CcSEcCtD
Bosutinib—CDK2—adipose tissue—metabolic syndrome X	0.00238	0.00651	CbGeAlD
Bosutinib—PLK2—cardiovascular system—metabolic syndrome X	0.00238	0.00651	CbGeAlD
Bosutinib—STK26—adipose tissue—metabolic syndrome X	0.00236	0.00645	CbGeAlD
Bosutinib—Nasopharyngitis—Metformin—metabolic syndrome X	0.00234	0.0316	CcSEcCtD
Bosutinib—PLK2—kidney—metabolic syndrome X	0.00233	0.00636	CbGeAlD
Bosutinib—CHEK2—adipose tissue—metabolic syndrome X	0.00228	0.00623	CbGeAlD
Bosutinib—Influenza—Metformin—metabolic syndrome X	0.00227	0.0306	CcSEcCtD
Bosutinib—DMPK—adipose tissue—metabolic syndrome X	0.00226	0.00618	CbGeAlD
Bosutinib—WEE1—adipose tissue—metabolic syndrome X	0.00226	0.00618	CbGeAlD
Bosutinib—Abdominal discomfort—Metformin—metabolic syndrome X	0.00217	0.0293	CcSEcCtD
Bosutinib—STK25—adipose tissue—metabolic syndrome X	0.00216	0.0059	CbGeAlD
Bosutinib—EPHA3—adipose tissue—metabolic syndrome X	0.00215	0.00586	CbGeAlD
Bosutinib—PDGFRB—blood vessel—metabolic syndrome X	0.00212	0.00579	CbGeAlD
Bosutinib—Neutropenia—Metformin—metabolic syndrome X	0.00212	0.0286	CcSEcCtD
Bosutinib—Upper respiratory tract infection—Metformin—metabolic syndrome X	0.00211	0.0284	CcSEcCtD
Bosutinib—PLK2—adipose tissue—metabolic syndrome X	0.0021	0.00574	CbGeAlD
Bosutinib—SIK3—adipose tissue—metabolic syndrome X	0.00209	0.0057	CbGeAlD
Bosutinib—Infestation NOS—Metformin—metabolic syndrome X	0.00202	0.0273	CcSEcCtD
Bosutinib—Infestation—Metformin—metabolic syndrome X	0.00202	0.0273	CcSEcCtD
Bosutinib—ERBB4—cardiovascular system—metabolic syndrome X	0.00201	0.00549	CbGeAlD
Bosutinib—STK4—adipose tissue—metabolic syndrome X	0.00201	0.00549	CbGeAlD
Bosutinib—ROCK1—cardiovascular system—metabolic syndrome X	0.00199	0.00542	CbGeAlD
Bosutinib—TLK1—liver—metabolic syndrome X	0.00199	0.00542	CbGeAlD
Bosutinib—CAMK1D—adipose tissue—metabolic syndrome X	0.00199	0.00542	CbGeAlD
Bosutinib—STK24—adipose tissue—metabolic syndrome X	0.00196	0.00536	CbGeAlD
Bosutinib—PRKCQ—liver—metabolic syndrome X	0.00196	0.00534	CbGeAlD
Bosutinib—ROCK1—kidney—metabolic syndrome X	0.00194	0.00531	CbGeAlD
Bosutinib—SIK2—liver—metabolic syndrome X	0.00193	0.00527	CbGeAlD
Bosutinib—BMPR2—cardiovascular system—metabolic syndrome X	0.00193	0.00527	CbGeAlD
Bosutinib—Hepatobiliary disease—Metformin—metabolic syndrome X	0.00191	0.0258	CcSEcCtD
Bosutinib—FER—adipose tissue—metabolic syndrome X	0.0019	0.00518	CbGeAlD
Bosutinib—BMPR2—kidney—metabolic syndrome X	0.00189	0.00515	CbGeAlD
Bosutinib—FRK—liver—metabolic syndrome X	0.00188	0.00514	CbGeAlD
Bosutinib—MAP4K1—adipose tissue—metabolic syndrome X	0.00186	0.00508	CbGeAlD
Bosutinib—MAP4K4—cardiovascular system—metabolic syndrome X	0.00186	0.00507	CbGeAlD
Bosutinib—BTK—adipose tissue—metabolic syndrome X	0.00185	0.00505	CbGeAlD
Bosutinib—CLK3—liver—metabolic syndrome X	0.00184	0.00502	CbGeAlD
Bosutinib—TNK2—adipose tissue—metabolic syndrome X	0.00182	0.00498	CbGeAlD
Bosutinib—MAP4K4—kidney—metabolic syndrome X	0.00182	0.00496	CbGeAlD
Bosutinib—Hepatitis—Metformin—metabolic syndrome X	0.00181	0.0245	CcSEcCtD
Bosutinib—MAP4K2—adipose tissue—metabolic syndrome X	0.0018	0.00491	CbGeAlD
Bosutinib—CASK—liver—metabolic syndrome X	0.0018	0.0049	CbGeAlD
Bosutinib—MAP2K1—cardiovascular system—metabolic syndrome X	0.00179	0.0049	CbGeAlD
Bosutinib—Oedema peripheral—Metformin—metabolic syndrome X	0.00179	0.0241	CcSEcCtD
Bosutinib—Connective tissue disorder—Metformin—metabolic syndrome X	0.00178	0.0241	CcSEcCtD
Bosutinib—CSK—cardiovascular system—metabolic syndrome X	0.00178	0.00486	CbGeAlD
Bosutinib—EIF2AK1—liver—metabolic syndrome X	0.00178	0.00485	CbGeAlD
Bosutinib—STK3—adipose tissue—metabolic syndrome X	0.00177	0.00485	CbGeAlD
Bosutinib—ERBB4—adipose tissue—metabolic syndrome X	0.00177	0.00485	CbGeAlD
Bosutinib—CSNK1A1—cardiovascular system—metabolic syndrome X	0.00177	0.00483	CbGeAlD
Bosutinib—CLK1—cardiovascular system—metabolic syndrome X	0.00176	0.0048	CbGeAlD
Bosutinib—MAP2K1—kidney—metabolic syndrome X	0.00176	0.00479	CbGeAlD
Bosutinib—CSK—kidney—metabolic syndrome X	0.00174	0.00476	CbGeAlD
Bosutinib—CSNK1A1—kidney—metabolic syndrome X	0.00173	0.00473	CbGeAlD
Bosutinib—CAMK2G—cardiovascular system—metabolic syndrome X	0.00173	0.00471	CbGeAlD
Bosutinib—FES—liver—metabolic syndrome X	0.00172	0.0047	CbGeAlD
Bosutinib—VRK2—liver—metabolic syndrome X	0.00172	0.0047	CbGeAlD
Bosutinib—CLK1—kidney—metabolic syndrome X	0.00172	0.0047	CbGeAlD
Bosutinib—BMPR2—adipose tissue—metabolic syndrome X	0.0017	0.00465	CbGeAlD
Bosutinib—TNIK—liver—metabolic syndrome X	0.00169	0.00461	CbGeAlD
Bosutinib—STK36—adipose tissue—metabolic syndrome X	0.00169	0.00461	CbGeAlD
Bosutinib—Cardiac disorder—Metformin—metabolic syndrome X	0.00168	0.0227	CcSEcCtD
Bosutinib—LRRK2—kidney—metabolic syndrome X	0.00167	0.00457	CbGeAlD
Bosutinib—CDK2—liver—metabolic syndrome X	0.00167	0.00457	CbGeAlD
Bosutinib—MERTK—adipose tissue—metabolic syndrome X	0.00167	0.00456	CbGeAlD
Bosutinib—PTK2B—cardiovascular system—metabolic syndrome X	0.00167	0.00455	CbGeAlD
Bosutinib—STK26—liver—metabolic syndrome X	0.00166	0.00452	CbGeAlD
Bosutinib—Immune system disorder—Metformin—metabolic syndrome X	0.00164	0.0221	CcSEcCtD
Bosutinib—MAP4K4—adipose tissue—metabolic syndrome X	0.00164	0.00447	CbGeAlD
Bosutinib—Mediastinal disorder—Metformin—metabolic syndrome X	0.00163	0.0221	CcSEcCtD
Bosutinib—PTK2B—kidney—metabolic syndrome X	0.00163	0.00445	CbGeAlD
Bosutinib—NUAK2—adipose tissue—metabolic syndrome X	0.00163	0.00444	CbGeAlD
Bosutinib—BCR—adipose tissue—metabolic syndrome X	0.00163	0.00444	CbGeAlD
Bosutinib—MAP3K12—adipose tissue—metabolic syndrome X	0.00161	0.00441	CbGeAlD
Bosutinib—DMPK—liver—metabolic syndrome X	0.00159	0.00433	CbGeAlD
Bosutinib—WEE1—liver—metabolic syndrome X	0.00159	0.00433	CbGeAlD
Bosutinib—MAP2K1—adipose tissue—metabolic syndrome X	0.00158	0.00432	CbGeAlD
Bosutinib—STK35—adipose tissue—metabolic syndrome X	0.00158	0.00432	CbGeAlD
Bosutinib—SIK1—kidney—metabolic syndrome X	0.00158	0.00431	CbGeAlD
Bosutinib—MAP2K2—cardiovascular system—metabolic syndrome X	0.00158	0.00431	CbGeAlD
Bosutinib—Malnutrition—Metformin—metabolic syndrome X	0.00158	0.0213	CcSEcCtD
Bosutinib—CSK—adipose tissue—metabolic syndrome X	0.00157	0.00429	CbGeAlD
Bosutinib—CSNK1A1—adipose tissue—metabolic syndrome X	0.00156	0.00426	CbGeAlD
Bosutinib—HCK—adipose tissue—metabolic syndrome X	0.00155	0.00423	CbGeAlD
Bosutinib—CLK1—adipose tissue—metabolic syndrome X	0.00155	0.00423	CbGeAlD
Bosutinib—ERBB3—kidney—metabolic syndrome X	0.00155	0.00423	CbGeAlD
Bosutinib—Dysgeusia—Metformin—metabolic syndrome X	0.00155	0.0209	CcSEcCtD
Bosutinib—MAP2K2—kidney—metabolic syndrome X	0.00155	0.00422	CbGeAlD
Bosutinib—ABL2—adipose tissue—metabolic syndrome X	0.00154	0.00421	CbGeAlD
Bosutinib—TBK1—cardiovascular system—metabolic syndrome X	0.00154	0.00419	CbGeAlD
Bosutinib—PTK2—cardiovascular system—metabolic syndrome X	0.00154	0.00419	CbGeAlD
Bosutinib—BMP2K—adipose tissue—metabolic syndrome X	0.00152	0.00416	CbGeAlD
Bosutinib—CAMK2G—adipose tissue—metabolic syndrome X	0.00152	0.00416	CbGeAlD
Bosutinib—STK25—liver—metabolic syndrome X	0.00152	0.00414	CbGeAlD
Bosutinib—LRRK2—adipose tissue—metabolic syndrome X	0.00151	0.00412	CbGeAlD
Bosutinib—EGFR—adipose tissue—metabolic syndrome X	0.0015	0.00411	CbGeAlD
Bosutinib—PTK2—kidney—metabolic syndrome X	0.0015	0.0041	CbGeAlD
Bosutinib—TBK1—kidney—metabolic syndrome X	0.0015	0.0041	CbGeAlD
Bosutinib—RPS6KB1—cardiovascular system—metabolic syndrome X	0.00148	0.00403	CbGeAlD
Bosutinib—PLK2—liver—metabolic syndrome X	0.00147	0.00402	CbGeAlD
Bosutinib—PTK2B—adipose tissue—metabolic syndrome X	0.00147	0.00401	CbGeAlD
Bosutinib—FGR—cardiovascular system—metabolic syndrome X	0.00147	0.00401	CbGeAlD
Bosutinib—Ill-defined disorder—Metformin—metabolic syndrome X	0.00147	0.0198	CcSEcCtD
Bosutinib—SIK3—liver—metabolic syndrome X	0.00146	0.004	CbGeAlD
Bosutinib—AXL—cardiovascular system—metabolic syndrome X	0.00146	0.00399	CbGeAlD
Bosutinib—CSNK1E—adipose tissue—metabolic syndrome X	0.00145	0.00395	CbGeAlD
Bosutinib—RPS6KB1—kidney—metabolic syndrome X	0.00145	0.00395	CbGeAlD
Bosutinib—IRAK4—adipose tissue—metabolic syndrome X	0.00142	0.00389	CbGeAlD
Bosutinib—SIK1—adipose tissue—metabolic syndrome X	0.00142	0.00389	CbGeAlD
Bosutinib—Malaise—Metformin—metabolic syndrome X	0.00142	0.0192	CcSEcCtD
Bosutinib—EPHA4—adipose tissue—metabolic syndrome X	0.00141	0.00385	CbGeAlD
Bosutinib—STK4—liver—metabolic syndrome X	0.00141	0.00385	CbGeAlD
Bosutinib—EPHB4—cardiovascular system—metabolic syndrome X	0.0014	0.00382	CbGeAlD
Bosutinib—ERBB3—adipose tissue—metabolic syndrome X	0.0014	0.00381	CbGeAlD
Bosutinib—MAP2K2—adipose tissue—metabolic syndrome X	0.00139	0.0038	CbGeAlD
Bosutinib—ULK3—adipose tissue—metabolic syndrome X	0.00139	0.0038	CbGeAlD
Bosutinib—CAMK1D—liver—metabolic syndrome X	0.00139	0.0038	CbGeAlD
Bosutinib—MAP3K2—adipose tissue—metabolic syndrome X	0.00138	0.00377	CbGeAlD
Bosutinib—STK24—liver—metabolic syndrome X	0.00138	0.00376	CbGeAlD
Bosutinib—EPHA2—cardiovascular system—metabolic syndrome X	0.00137	0.00374	CbGeAlD
Bosutinib—MAP3K7—adipose tissue—metabolic syndrome X	0.00137	0.00374	CbGeAlD
Bosutinib—FYN—cardiovascular system—metabolic syndrome X	0.00137	0.00374	CbGeAlD
Bosutinib—EPHB4—kidney—metabolic syndrome X	0.00137	0.00373	CbGeAlD
Bosutinib—TBK1—adipose tissue—metabolic syndrome X	0.00135	0.0037	CbGeAlD
Bosutinib—PTK2—adipose tissue—metabolic syndrome X	0.00135	0.0037	CbGeAlD
Bosutinib—Myalgia—Metformin—metabolic syndrome X	0.00134	0.0181	CcSEcCtD
Bosutinib—Chest pain—Metformin—metabolic syndrome X	0.00134	0.0181	CcSEcCtD
Bosutinib—FYN—kidney—metabolic syndrome X	0.00134	0.00366	CbGeAlD
Bosutinib—MAP3K3—cardiovascular system—metabolic syndrome X	0.00134	0.00365	CbGeAlD
Bosutinib—Unspecified disorder of skin and subcutaneous tissue—Metformin—metabolic syndrome X	0.00134	0.018	CcSEcCtD
Bosutinib—FER—liver—metabolic syndrome X	0.00133	0.00364	CbGeAlD
Bosutinib—Discomfort—Metformin—metabolic syndrome X	0.00133	0.0179	CcSEcCtD
Bosutinib—IRAK1—adipose tissue—metabolic syndrome X	0.00133	0.00362	CbGeAlD
Bosutinib—LYN—liver—metabolic syndrome X	0.00132	0.00362	CbGeAlD
Bosutinib—RPS6KB1—adipose tissue—metabolic syndrome X	0.0013	0.00356	CbGeAlD
Bosutinib—BTK—liver—metabolic syndrome X	0.0013	0.00354	CbGeAlD
Bosutinib—LCK—adipose tissue—metabolic syndrome X	0.00129	0.00353	CbGeAlD
Bosutinib—FGR—adipose tissue—metabolic syndrome X	0.00129	0.00353	CbGeAlD
Bosutinib—AXL—adipose tissue—metabolic syndrome X	0.00129	0.00352	CbGeAlD
Bosutinib—Oedema—Metformin—metabolic syndrome X	0.00129	0.0174	CcSEcCtD
Bosutinib—Infection—Metformin—metabolic syndrome X	0.00128	0.0173	CcSEcCtD
Bosutinib—TNK2—liver—metabolic syndrome X	0.00128	0.00349	CbGeAlD
Bosutinib—Nervous system disorder—Metformin—metabolic syndrome X	0.00126	0.0171	CcSEcCtD
Bosutinib—MAP4K2—liver—metabolic syndrome X	0.00126	0.00344	CbGeAlD
Bosutinib—Thrombocytopenia—Metformin—metabolic syndrome X	0.00126	0.017	CcSEcCtD
Bosutinib—Skin disorder—Metformin—metabolic syndrome X	0.00125	0.0169	CcSEcCtD
Bosutinib—STK3—liver—metabolic syndrome X	0.00124	0.0034	CbGeAlD
Bosutinib—SLK—adipose tissue—metabolic syndrome X	0.00124	0.00339	CbGeAlD
Bosutinib—EPHB4—adipose tissue—metabolic syndrome X	0.00123	0.00336	CbGeAlD
Bosutinib—ROCK1—liver—metabolic syndrome X	0.00123	0.00335	CbGeAlD
Bosutinib—STK10—cardiovascular system—metabolic syndrome X	0.00122	0.00334	CbGeAlD
Bosutinib—TAOK3—cardiovascular system—metabolic syndrome X	0.00122	0.00333	CbGeAlD
Bosutinib—EPHA2—adipose tissue—metabolic syndrome X	0.00121	0.0033	CbGeAlD
Bosutinib—YES1—kidney—metabolic syndrome X	0.00121	0.0033	CbGeAlD
Bosutinib—FYN—adipose tissue—metabolic syndrome X	0.00121	0.00329	CbGeAlD
Bosutinib—STK10—kidney—metabolic syndrome X	0.0012	0.00327	CbGeAlD
Bosutinib—BMPR2—liver—metabolic syndrome X	0.00119	0.00326	CbGeAlD
Bosutinib—TAOK3—kidney—metabolic syndrome X	0.00119	0.00326	CbGeAlD
Bosutinib—SRC—cardiovascular system—metabolic syndrome X	0.00119	0.00324	CbGeAlD
Bosutinib—STK36—liver—metabolic syndrome X	0.00118	0.00323	CbGeAlD
Bosutinib—MAP3K3—adipose tissue—metabolic syndrome X	0.00118	0.00322	CbGeAlD
Bosutinib—MAP4K5—adipose tissue—metabolic syndrome X	0.00118	0.00322	CbGeAlD
Bosutinib—Musculoskeletal discomfort—Metformin—metabolic syndrome X	0.00117	0.0158	CcSEcCtD
Bosutinib—MERTK—liver—metabolic syndrome X	0.00117	0.00319	CbGeAlD
Bosutinib—SRC—kidney—metabolic syndrome X	0.00116	0.00317	CbGeAlD
Bosutinib—Dyspnoea—Metformin—metabolic syndrome X	0.00115	0.0155	CcSEcCtD
Bosutinib—MAP4K4—liver—metabolic syndrome X	0.00115	0.00314	CbGeAlD
Bosutinib—NUAK2—liver—metabolic syndrome X	0.00114	0.00311	CbGeAlD
Bosutinib—BCR—liver—metabolic syndrome X	0.00114	0.00311	CbGeAlD
Bosutinib—MAP3K12—liver—metabolic syndrome X	0.00113	0.00309	CbGeAlD
Bosutinib—Decreased appetite—Metformin—metabolic syndrome X	0.00112	0.0151	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Metformin—metabolic syndrome X	0.00111	0.015	CcSEcCtD
Bosutinib—Fatigue—Metformin—metabolic syndrome X	0.00111	0.015	CcSEcCtD
Bosutinib—MAP2K1—liver—metabolic syndrome X	0.00111	0.00303	CbGeAlD
Bosutinib—STK35—liver—metabolic syndrome X	0.00111	0.00303	CbGeAlD
Bosutinib—CSK—liver—metabolic syndrome X	0.0011	0.00301	CbGeAlD
Bosutinib—CSNK1A1—liver—metabolic syndrome X	0.00109	0.00299	CbGeAlD
Bosutinib—MAP2K5—cardiovascular system—metabolic syndrome X	0.00109	0.00298	CbGeAlD
Bosutinib—YES1—adipose tissue—metabolic syndrome X	0.00109	0.00297	CbGeAlD
Bosutinib—HCK—liver—metabolic syndrome X	0.00109	0.00297	CbGeAlD
Bosutinib—CLK1—liver—metabolic syndrome X	0.00109	0.00297	CbGeAlD
Bosutinib—ABL2—liver—metabolic syndrome X	0.00108	0.00295	CbGeAlD
Bosutinib—STK10—adipose tissue—metabolic syndrome X	0.00108	0.00295	CbGeAlD
Bosutinib—TAOK3—adipose tissue—metabolic syndrome X	0.00108	0.00294	CbGeAlD
Bosutinib—CAMK2G—liver—metabolic syndrome X	0.00107	0.00292	CbGeAlD
Bosutinib—BMP2K—liver—metabolic syndrome X	0.00107	0.00292	CbGeAlD
Bosutinib—CSF1R—cardiovascular system—metabolic syndrome X	0.00107	0.00291	CbGeAlD
Bosutinib—Feeling abnormal—Metformin—metabolic syndrome X	0.00106	0.0143	CcSEcCtD
Bosutinib—LRRK2—liver—metabolic syndrome X	0.00106	0.00289	CbGeAlD
Bosutinib—EGFR—liver—metabolic syndrome X	0.00106	0.00288	CbGeAlD
Bosutinib—Gastrointestinal pain—Metformin—metabolic syndrome X	0.00105	0.0142	CcSEcCtD
Bosutinib—SRC—adipose tissue—metabolic syndrome X	0.00105	0.00286	CbGeAlD
Bosutinib—Vandetanib—ALB—metabolic syndrome X	0.00103	0.0771	CrCbGaD
Bosutinib—PTK2B—liver—metabolic syndrome X	0.00103	0.00282	CbGeAlD
Bosutinib—Urticaria—Metformin—metabolic syndrome X	0.00102	0.0138	CcSEcCtD
Bosutinib—Abdominal pain—Metformin—metabolic syndrome X	0.00102	0.0137	CcSEcCtD
Bosutinib—CSNK1E—liver—metabolic syndrome X	0.00101	0.00277	CbGeAlD
Bosutinib—SIK1—liver—metabolic syndrome X	0.000999	0.00273	CbGeAlD
Bosutinib—IRAK4—liver—metabolic syndrome X	0.000999	0.00273	CbGeAlD
Bosutinib—Gefitinib—ALB—metabolic syndrome X	0.000982	0.0732	CrCbGaD
Bosutinib—ERBB3—liver—metabolic syndrome X	0.000979	0.00267	CbGeAlD
Bosutinib—MAP2K2—liver—metabolic syndrome X	0.000977	0.00267	CbGeAlD
Bosutinib—ULK3—liver—metabolic syndrome X	0.000977	0.00267	CbGeAlD
Bosutinib—MAP3K2—liver—metabolic syndrome X	0.00097	0.00265	CbGeAlD
Bosutinib—MAP2K5—adipose tissue—metabolic syndrome X	0.000964	0.00263	CbGeAlD
Bosutinib—MAP3K7—liver—metabolic syndrome X	0.000961	0.00262	CbGeAlD
Bosutinib—PTK2—liver—metabolic syndrome X	0.00095	0.00259	CbGeAlD
Bosutinib—TBK1—liver—metabolic syndrome X	0.00095	0.00259	CbGeAlD
Bosutinib—PDGFRB—cardiovascular system—metabolic syndrome X	0.000946	0.00258	CbGeAlD
Bosutinib—CSF1R—adipose tissue—metabolic syndrome X	0.000941	0.00257	CbGeAlD
Bosutinib—IRAK1—liver—metabolic syndrome X	0.000931	0.00254	CbGeAlD
Bosutinib—PDGFRB—kidney—metabolic syndrome X	0.000926	0.00253	CbGeAlD
Bosutinib—Asthenia—Metformin—metabolic syndrome X	0.000925	0.0125	CcSEcCtD
Bosutinib—RPS6KB1—liver—metabolic syndrome X	0.000914	0.00249	CbGeAlD
Bosutinib—Pruritus—Metformin—metabolic syndrome X	0.000912	0.0123	CcSEcCtD
Bosutinib—FGR—liver—metabolic syndrome X	0.000908	0.00248	CbGeAlD
Bosutinib—LCK—liver—metabolic syndrome X	0.000908	0.00248	CbGeAlD
Bosutinib—AXL—liver—metabolic syndrome X	0.000904	0.00247	CbGeAlD
Bosutinib—Diarrhoea—Metformin—metabolic syndrome X	0.000882	0.0119	CcSEcCtD
Bosutinib—SLK—liver—metabolic syndrome X	0.000871	0.00238	CbGeAlD
Bosutinib—EPHB4—liver—metabolic syndrome X	0.000864	0.00236	CbGeAlD
Bosutinib—Dizziness—Metformin—metabolic syndrome X	0.000852	0.0115	CcSEcCtD
Bosutinib—EPHA2—liver—metabolic syndrome X	0.000848	0.00231	CbGeAlD
Bosutinib—FYN—liver—metabolic syndrome X	0.000846	0.00231	CbGeAlD
Bosutinib—ABL1—cardiovascular system—metabolic syndrome X	0.000843	0.0023	CbGeAlD
Bosutinib—PDGFRB—adipose tissue—metabolic syndrome X	0.000834	0.00228	CbGeAlD
Bosutinib—MAP4K5—liver—metabolic syndrome X	0.000827	0.00226	CbGeAlD
Bosutinib—MAP3K3—liver—metabolic syndrome X	0.000827	0.00226	CbGeAlD
Bosutinib—ABL1—kidney—metabolic syndrome X	0.000825	0.00225	CbGeAlD
Bosutinib—Vomiting—Metformin—metabolic syndrome X	0.000819	0.0111	CcSEcCtD
Bosutinib—Rash—Metformin—metabolic syndrome X	0.000813	0.011	CcSEcCtD
Bosutinib—Dermatitis—Metformin—metabolic syndrome X	0.000812	0.011	CcSEcCtD
Bosutinib—Headache—Metformin—metabolic syndrome X	0.000807	0.0109	CcSEcCtD
Bosutinib—Nausea—Metformin—metabolic syndrome X	0.000765	0.0103	CcSEcCtD
Bosutinib—YES1—liver—metabolic syndrome X	0.000764	0.00209	CbGeAlD
Bosutinib—STK10—liver—metabolic syndrome X	0.000757	0.00207	CbGeAlD
Bosutinib—TAOK3—liver—metabolic syndrome X	0.000754	0.00206	CbGeAlD
Bosutinib—ABL1—adipose tissue—metabolic syndrome X	0.000744	0.00203	CbGeAlD
Bosutinib—SRC—liver—metabolic syndrome X	0.000735	0.00201	CbGeAlD
Bosutinib—MAP2K5—liver—metabolic syndrome X	0.000676	0.00185	CbGeAlD
Bosutinib—CSF1R—liver—metabolic syndrome X	0.00066	0.0018	CbGeAlD
Bosutinib—ABCB1—blood vessel—metabolic syndrome X	0.000588	0.0016	CbGeAlD
Bosutinib—PDGFRB—liver—metabolic syndrome X	0.000585	0.0016	CbGeAlD
Bosutinib—ABL1—liver—metabolic syndrome X	0.000522	0.00142	CbGeAlD
Bosutinib—CYP3A4—kidney—metabolic syndrome X	0.000362	0.000989	CbGeAlD
Bosutinib—ABCB1—cardiovascular system—metabolic syndrome X	0.000262	0.000716	CbGeAlD
Bosutinib—ABCB1—kidney—metabolic syndrome X	0.000257	0.0007	CbGeAlD
Bosutinib—ABCB1—adipose tissue—metabolic syndrome X	0.000231	0.000631	CbGeAlD
Bosutinib—CYP3A4—liver—metabolic syndrome X	0.000229	0.000625	CbGeAlD
Bosutinib—ABCB1—liver—metabolic syndrome X	0.000162	0.000443	CbGeAlD
Bosutinib—MAP2K2—Signaling Pathways—CCL2—metabolic syndrome X	7.92e-06	1.45e-05	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—IRS1—metabolic syndrome X	7.91e-06	1.45e-05	CbGpPWpGaD
Bosutinib—LYN—Adaptive Immune System—AKT1—metabolic syndrome X	7.91e-06	1.45e-05	CbGpPWpGaD
Bosutinib—LCK—Disease—NOS3—metabolic syndrome X	7.89e-06	1.45e-05	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—GOT2—metabolic syndrome X	7.88e-06	1.44e-05	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—HMGCR—metabolic syndrome X	7.88e-06	1.44e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—IRS1—metabolic syndrome X	7.86e-06	1.44e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—INS—metabolic syndrome X	7.86e-06	1.44e-05	CbGpPWpGaD
Bosutinib—SYK—Signaling Pathways—AKT1—metabolic syndrome X	7.84e-06	1.44e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—AGT—metabolic syndrome X	7.82e-06	1.43e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—LPL—metabolic syndrome X	7.79e-06	1.43e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—IGF1—metabolic syndrome X	7.79e-06	1.43e-05	CbGpPWpGaD
Bosutinib—FYN—Adaptive Immune System—AKT1—metabolic syndrome X	7.78e-06	1.43e-05	CbGpPWpGaD
Bosutinib—ABCB1—Transmembrane transport of small molecules—ALB—metabolic syndrome X	7.73e-06	1.42e-05	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—TGFB1—metabolic syndrome X	7.73e-06	1.42e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—CCL2—metabolic syndrome X	7.73e-06	1.42e-05	CbGpPWpGaD
Bosutinib—CSNK1A1—Signaling Pathways—AKT1—metabolic syndrome X	7.7e-06	1.41e-05	CbGpPWpGaD
Bosutinib—PRKCQ—Signaling Pathways—AKT1—metabolic syndrome X	7.7e-06	1.41e-05	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—INS—metabolic syndrome X	7.69e-06	1.41e-05	CbGpPWpGaD
Bosutinib—ERBB4—Disease—AKT1—metabolic syndrome X	7.67e-06	1.4e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—APOE—metabolic syndrome X	7.66e-06	1.4e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—LEP—metabolic syndrome X	7.66e-06	1.4e-05	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—TGFB1—metabolic syndrome X	7.62e-06	1.39e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—IGF1—metabolic syndrome X	7.6e-06	1.39e-05	CbGpPWpGaD
Bosutinib—EGFR—Innate Immune System—IL6—metabolic syndrome X	7.59e-06	1.39e-05	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—INS—metabolic syndrome X	7.57e-06	1.39e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—APOA1—metabolic syndrome X	7.57e-06	1.39e-05	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—CCL2—metabolic syndrome X	7.57e-06	1.39e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—INS—metabolic syndrome X	7.53e-06	1.38e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—AGT—metabolic syndrome X	7.53e-06	1.38e-05	CbGpPWpGaD
Bosutinib—LCK—Hemostasis—AKT1—metabolic syndrome X	7.5e-06	1.37e-05	CbGpPWpGaD
Bosutinib—EGFR—Disease—PTGS2—metabolic syndrome X	7.49e-06	1.37e-05	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—CCL2—metabolic syndrome X	7.45e-06	1.36e-05	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—IGF1—metabolic syndrome X	7.44e-06	1.36e-05	CbGpPWpGaD
Bosutinib—CSK—Signaling Pathways—AKT1—metabolic syndrome X	7.43e-06	1.36e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—CCL2—metabolic syndrome X	7.41e-06	1.36e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—SERPINE1—metabolic syndrome X	7.39e-06	1.35e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—LEP—metabolic syndrome X	7.38e-06	1.35e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—APOE—metabolic syndrome X	7.38e-06	1.35e-05	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—G6PD—metabolic syndrome X	7.35e-06	1.35e-05	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—TGFB1—metabolic syndrome X	7.34e-06	1.34e-05	CbGpPWpGaD
Bosutinib—SRC—Developmental Biology—IL6—metabolic syndrome X	7.33e-06	1.34e-05	CbGpPWpGaD
Bosutinib—ERBB3—Disease—IL6—metabolic syndrome X	7.33e-06	1.34e-05	CbGpPWpGaD
Bosutinib—ERBB3—Immune System—AKT1—metabolic syndrome X	7.33e-06	1.34e-05	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—IGF1—metabolic syndrome X	7.32e-06	1.34e-05	CbGpPWpGaD
Bosutinib—SRC—Disease—SERPINE1—metabolic syndrome X	7.32e-06	1.34e-05	CbGpPWpGaD
Bosutinib—LCK—Innate Immune System—IL6—metabolic syndrome X	7.32e-06	1.34e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—APOA1—metabolic syndrome X	7.3e-06	1.34e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—IGF1—metabolic syndrome X	7.29e-06	1.33e-05	CbGpPWpGaD
Bosutinib—LCK—Disease—PTGS2—metabolic syndrome X	7.22e-06	1.32e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—SERPINE1—metabolic syndrome X	7.22e-06	1.32e-05	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—HDAC3—metabolic syndrome X	7.17e-06	1.31e-05	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—TGFB1—metabolic syndrome X	7.07e-06	1.29e-05	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—TGFB1—metabolic syndrome X	7.07e-06	1.29e-05	CbGpPWpGaD
Bosutinib—PTK2—Immune System—IL6—metabolic syndrome X	7.07e-06	1.29e-05	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—SERPINE1—metabolic syndrome X	7.06e-06	1.29e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—NOS3—metabolic syndrome X	7.06e-06	1.29e-05	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—ABCA1—metabolic syndrome X	7.03e-06	1.29e-05	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—SLC2A4—metabolic syndrome X	7.03e-06	1.29e-05	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—LPA—metabolic syndrome X	7.01e-06	1.28e-05	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—GCKR—metabolic syndrome X	7.01e-06	1.28e-05	CbGpPWpGaD
Bosutinib—EGFR—Innate Immune System—AKT1—metabolic syndrome X	7e-06	1.28e-05	CbGpPWpGaD
Bosutinib—SRC—Disease—NOS3—metabolic syndrome X	6.99e-06	1.28e-05	CbGpPWpGaD
Bosutinib—YES1—Immune System—IL6—metabolic syndrome X	6.97e-06	1.28e-05	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—SERPINE1—metabolic syndrome X	6.96e-06	1.27e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—SERPINE1—metabolic syndrome X	6.92e-06	1.27e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—NOS3—metabolic syndrome X	6.89e-06	1.26e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—IRS1—metabolic syndrome X	6.83e-06	1.25e-05	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—TGFB1—metabolic syndrome X	6.81e-06	1.25e-05	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—GGT1—metabolic syndrome X	6.81e-06	1.25e-05	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—GOT1—metabolic syndrome X	6.81e-06	1.25e-05	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PLA2G6—metabolic syndrome X	6.79e-06	1.24e-05	CbGpPWpGaD
Bosutinib—SRC—Developmental Biology—AKT1—metabolic syndrome X	6.76e-06	1.24e-05	CbGpPWpGaD
Bosutinib—ERBB3—Disease—AKT1—metabolic syndrome X	6.76e-06	1.24e-05	CbGpPWpGaD
Bosutinib—LCK—Innate Immune System—AKT1—metabolic syndrome X	6.75e-06	1.24e-05	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—NOS3—metabolic syndrome X	6.74e-06	1.23e-05	CbGpPWpGaD
Bosutinib—CSNK1E—Signaling Pathways—IL6—metabolic syndrome X	6.74e-06	1.23e-05	CbGpPWpGaD
Bosutinib—EGFR—Adaptive Immune System—AKT1—metabolic syndrome X	6.72e-06	1.23e-05	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—APOA5—metabolic syndrome X	6.72e-06	1.23e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—AGT—metabolic syndrome X	6.67e-06	1.22e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—TGFB1—metabolic syndrome X	6.67e-06	1.22e-05	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—NOS3—metabolic syndrome X	6.64e-06	1.22e-05	CbGpPWpGaD
Bosutinib—SRC—Hemostasis—AKT1—metabolic syndrome X	6.64e-06	1.22e-05	CbGpPWpGaD
Bosutinib—IRAK1—Immune System—IL6—metabolic syndrome X	6.61e-06	1.21e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—NOS3—metabolic syndrome X	6.6e-06	1.21e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—IRS1—metabolic syndrome X	6.58e-06	1.21e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—INS—metabolic syndrome X	6.54e-06	1.2e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—LEP—metabolic syndrome X	6.53e-06	1.2e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—APOE—metabolic syndrome X	6.53e-06	1.2e-05	CbGpPWpGaD
Bosutinib—PTK2—Immune System—AKT1—metabolic syndrome X	6.52e-06	1.19e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—TGFB1—metabolic syndrome X	6.51e-06	1.19e-05	CbGpPWpGaD
Bosutinib—LCK—Adaptive Immune System—AKT1—metabolic syndrome X	6.48e-06	1.19e-05	CbGpPWpGaD
Bosutinib—SRC—Innate Immune System—IL6—metabolic syndrome X	6.48e-06	1.19e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—APOA1—metabolic syndrome X	6.46e-06	1.18e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—CCL2—metabolic syndrome X	6.44e-06	1.18e-05	CbGpPWpGaD
Bosutinib—YES1—Immune System—AKT1—metabolic syndrome X	6.43e-06	1.18e-05	CbGpPWpGaD
Bosutinib—SRC—Disease—PTGS2—metabolic syndrome X	6.39e-06	1.17e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—IGF1—metabolic syndrome X	6.33e-06	1.16e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—INS—metabolic syndrome X	6.3e-06	1.15e-05	CbGpPWpGaD
Bosutinib—FYN—Disease—TGFB1—metabolic syndrome X	6.27e-06	1.15e-05	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—TRIB3—metabolic syndrome X	6.25e-06	1.14e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—TGFB1—metabolic syndrome X	6.24e-06	1.14e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Immune System—IL6—metabolic syndrome X	6.23e-06	1.14e-05	CbGpPWpGaD
Bosutinib—CSNK1E—Signaling Pathways—AKT1—metabolic syndrome X	6.22e-06	1.14e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—CCL2—metabolic syndrome X	6.2e-06	1.14e-05	CbGpPWpGaD
Bosutinib—IRAK1—Immune System—AKT1—metabolic syndrome X	6.1e-06	1.12e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—IGF1—metabolic syndrome X	6.1e-06	1.12e-05	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—TGFB1—metabolic syndrome X	6.07e-06	1.11e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—SERPINE1—metabolic syndrome X	6.01e-06	1.1e-05	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—TGFB1—metabolic syndrome X	5.98e-06	1.1e-05	CbGpPWpGaD
Bosutinib—SRC—Innate Immune System—AKT1—metabolic syndrome X	5.97e-06	1.09e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling by GPCR—IL6—metabolic syndrome X	5.95e-06	1.09e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—IRS1—metabolic syndrome X	5.83e-06	1.07e-05	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—IL6—metabolic syndrome X	5.82e-06	1.07e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—SERPINE1—metabolic syndrome X	5.79e-06	1.06e-05	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—APOB—metabolic syndrome X	5.78e-06	1.06e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Immune System—AKT1—metabolic syndrome X	5.74e-06	1.05e-05	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—IL6—metabolic syndrome X	5.74e-06	1.05e-05	CbGpPWpGaD
Bosutinib—SRC—Adaptive Immune System—AKT1—metabolic syndrome X	5.74e-06	1.05e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—NOS3—metabolic syndrome X	5.74e-06	1.05e-05	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—TGFB1—metabolic syndrome X	5.67e-06	1.04e-05	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—PLA2G4A—metabolic syndrome X	5.62e-06	1.03e-05	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—NAMPT—metabolic syndrome X	5.6e-06	1.03e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—INS—metabolic syndrome X	5.58e-06	1.02e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling by GPCR—IL6—metabolic syndrome X	5.57e-06	1.02e-05	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—LIPC—metabolic syndrome X	5.57e-06	1.02e-05	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—GCK—metabolic syndrome X	5.57e-06	1.02e-05	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—APOC3—metabolic syndrome X	5.53e-06	1.01e-05	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—IL6—metabolic syndrome X	5.53e-06	1.01e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—NOS3—metabolic syndrome X	5.53e-06	1.01e-05	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—LPL—metabolic syndrome X	5.51e-06	1.01e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling by GPCR—AKT1—metabolic syndrome X	5.49e-06	1.01e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—CCL2—metabolic syndrome X	5.49e-06	1.01e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Immune System—IL6—metabolic syndrome X	5.44e-06	9.96e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—TGFB1—metabolic syndrome X	5.42e-06	9.92e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—IGF1—metabolic syndrome X	5.4e-06	9.88e-06	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—AKT1—metabolic syndrome X	5.37e-06	9.84e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—CETP—metabolic syndrome X	5.37e-06	9.83e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—TGFB1—metabolic syndrome X	5.34e-06	9.78e-06	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—IL6—metabolic syndrome X	5.33e-06	9.75e-06	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—IL6—metabolic syndrome X	5.33e-06	9.75e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—IL6—metabolic syndrome X	5.31e-06	9.72e-06	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—AKT1—metabolic syndrome X	5.3e-06	9.7e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—CD36—metabolic syndrome X	5.24e-06	9.59e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—TGFB1—metabolic syndrome X	5.22e-06	9.56e-06	CbGpPWpGaD
Bosutinib—LYN—Immune System—IL6—metabolic syndrome X	5.2e-06	9.52e-06	CbGpPWpGaD
Bosutinib—ABL1—Immune System—IL6—metabolic syndrome X	5.17e-06	9.47e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—SCARB1—metabolic syndrome X	5.14e-06	9.42e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling by GPCR—AKT1—metabolic syndrome X	5.14e-06	9.41e-06	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—IL6—metabolic syndrome X	5.13e-06	9.4e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—SERPINE1—metabolic syndrome X	5.13e-06	9.39e-06	CbGpPWpGaD
Bosutinib—FYN—Immune System—IL6—metabolic syndrome X	5.12e-06	9.37e-06	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—AKT1—metabolic syndrome X	5.1e-06	9.34e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—IL6—metabolic syndrome X	5.09e-06	9.32e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—IL6—metabolic syndrome X	5.02e-06	9.2e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Immune System—AKT1—metabolic syndrome X	5.02e-06	9.19e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—SREBF1—metabolic syndrome X	4.99e-06	9.14e-06	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—AKT1—metabolic syndrome X	4.91e-06	9e-06	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—AKT1—metabolic syndrome X	4.91e-06	9e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—IL6—metabolic syndrome X	4.9e-06	8.98e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—AKT1—metabolic syndrome X	4.9e-06	8.97e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—NOS3—metabolic syndrome X	4.89e-06	8.96e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—PPARA—metabolic syndrome X	4.87e-06	8.92e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—HMGCR—metabolic syndrome X	4.86e-06	8.89e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—GOT2—metabolic syndrome X	4.86e-06	8.89e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling by GPCR—IL6—metabolic syndrome X	4.84e-06	8.86e-06	CbGpPWpGaD
Bosutinib—LYN—Immune System—AKT1—metabolic syndrome X	4.8e-06	8.78e-06	CbGpPWpGaD
Bosutinib—ABL1—Immune System—AKT1—metabolic syndrome X	4.77e-06	8.74e-06	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—AKT1—metabolic syndrome X	4.74e-06	8.67e-06	CbGpPWpGaD
Bosutinib—FYN—Disease—IL6—metabolic syndrome X	4.72e-06	8.65e-06	CbGpPWpGaD
Bosutinib—FYN—Immune System—AKT1—metabolic syndrome X	4.72e-06	8.64e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—AGT—metabolic syndrome X	4.72e-06	8.64e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—IL6—metabolic syndrome X	4.7e-06	8.6e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—AKT1—metabolic syndrome X	4.7e-06	8.6e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—TGFB1—metabolic syndrome X	4.67e-06	8.55e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—AKT1—metabolic syndrome X	4.63e-06	8.48e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—APOE—metabolic syndrome X	4.62e-06	8.46e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—TGFB1—metabolic syndrome X	4.62e-06	8.46e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—IL6—metabolic syndrome X	4.57e-06	8.37e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—APOA1—metabolic syndrome X	4.57e-06	8.37e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—TGFB1—metabolic syndrome X	4.56e-06	8.34e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—AKT1—metabolic syndrome X	4.52e-06	8.28e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—IL6—metabolic syndrome X	4.51e-06	8.25e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling by GPCR—AKT1—metabolic syndrome X	4.46e-06	8.17e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—TGFB1—metabolic syndrome X	4.46e-06	8.17e-06	CbGpPWpGaD
Bosutinib—EGFR—Immune System—IL6—metabolic syndrome X	4.42e-06	8.1e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—TGFB1—metabolic syndrome X	4.39e-06	8.04e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—TGFB1—metabolic syndrome X	4.37e-06	8e-06	CbGpPWpGaD
Bosutinib—FYN—Disease—AKT1—metabolic syndrome X	4.36e-06	7.98e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—AKT1—metabolic syndrome X	4.34e-06	7.94e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—ABCA1—metabolic syndrome X	4.33e-06	7.93e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—SLC2A4—metabolic syndrome X	4.33e-06	7.93e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—IL6—metabolic syndrome X	4.27e-06	7.83e-06	CbGpPWpGaD
Bosutinib—LCK—Immune System—IL6—metabolic syndrome X	4.26e-06	7.8e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—AKT1—metabolic syndrome X	4.22e-06	7.72e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—GGT1—metabolic syndrome X	4.19e-06	7.68e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—GOT1—metabolic syndrome X	4.19e-06	7.68e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—AKT1—metabolic syndrome X	4.16e-06	7.61e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—IL6—metabolic syndrome X	4.08e-06	7.47e-06	CbGpPWpGaD
Bosutinib—EGFR—Immune System—AKT1—metabolic syndrome X	4.08e-06	7.47e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—PPARG—metabolic syndrome X	4.03e-06	7.37e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—IL6—metabolic syndrome X	4.03e-06	7.37e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—INS—metabolic syndrome X	3.95e-06	7.23e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—AKT1—metabolic syndrome X	3.94e-06	7.22e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—IL6—metabolic syndrome X	3.93e-06	7.2e-06	CbGpPWpGaD
Bosutinib—LCK—Immune System—AKT1—metabolic syndrome X	3.93e-06	7.2e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—TGFB1—metabolic syndrome X	3.79e-06	6.95e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—IL6—metabolic syndrome X	3.77e-06	6.91e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—AKT1—metabolic syndrome X	3.77e-06	6.9e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—AKT1—metabolic syndrome X	3.71e-06	6.8e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—TGFB1—metabolic syndrome X	3.66e-06	6.69e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—AKT1—metabolic syndrome X	3.63e-06	6.64e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—ALB—metabolic syndrome X	3.62e-06	6.63e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—APOB—metabolic syndrome X	3.56e-06	6.51e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—IL6—metabolic syndrome X	3.52e-06	6.44e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—IL6—metabolic syndrome X	3.48e-06	6.38e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—AKT1—metabolic syndrome X	3.48e-06	6.37e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—NOS3—metabolic syndrome X	3.46e-06	6.34e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PLA2G4A—metabolic syndrome X	3.46e-06	6.34e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—IL6—metabolic syndrome X	3.43e-06	6.29e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—LPL—metabolic syndrome X	3.4e-06	6.22e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—IL6—metabolic syndrome X	3.36e-06	6.15e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—IL6—metabolic syndrome X	3.31e-06	6.06e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—IL6—metabolic syndrome X	3.29e-06	6.03e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—AKT1—metabolic syndrome X	3.25e-06	5.94e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—TGFB1—metabolic syndrome X	3.24e-06	5.93e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—CD36—metabolic syndrome X	3.23e-06	5.91e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—AKT1—metabolic syndrome X	3.21e-06	5.88e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—PTGS2—metabolic syndrome X	3.17e-06	5.8e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—AKT1—metabolic syndrome X	3.17e-06	5.8e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—AKT1—metabolic syndrome X	3.1e-06	5.68e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—AKT1—metabolic syndrome X	3.05e-06	5.59e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—AKT1—metabolic syndrome X	3.04e-06	5.56e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PPARA—metabolic syndrome X	3e-06	5.49e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—AGT—metabolic syndrome X	2.91e-06	5.32e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—IL6—metabolic syndrome X	2.86e-06	5.23e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—APOE—metabolic syndrome X	2.85e-06	5.21e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—APOA1—metabolic syndrome X	2.82e-06	5.15e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—IL6—metabolic syndrome X	2.75e-06	5.04e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—AKT1—metabolic syndrome X	2.64e-06	4.83e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—AKT1—metabolic syndrome X	2.54e-06	4.65e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PPARG—metabolic syndrome X	2.48e-06	4.54e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—IL6—metabolic syndrome X	2.44e-06	4.47e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—INS—metabolic syndrome X	2.43e-06	4.45e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—AKT1—metabolic syndrome X	2.25e-06	4.12e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—ALB—metabolic syndrome X	2.23e-06	4.08e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—NOS3—metabolic syndrome X	2.13e-06	3.91e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PTGS2—metabolic syndrome X	1.95e-06	3.57e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—AKT1—metabolic syndrome X	1.59e-06	2.91e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—AKT1—metabolic syndrome X	9.81e-07	1.8e-06	CbGpPWpGaD
